Showing 121 - 140 results of 120,565 for search '(( 2 e decrease ) OR ( 5 ((((mg decrease) OR (a decrease))) OR (nn decrease)) ))', query time: 1.59s Refine Results
  1. 121
  2. 122
  3. 123
  4. 124
  5. 125

    The number of behavioral arrests in DKO mice decreased following systemic atropine. by Mike Kalogiannis (224818)

    Published 2011
    “…<p>(A) Mean (± SEM) time per mouse spent in full behavioral arrests are plotted in 30 min bins across the entire recording period following IP injections of saline (open symbols) and atropine (0.5 mg/kg; filled symbols). …”
  6. 126
  7. 127
  8. 128

    EphA4 immunostaining is decreased adjacent to injury site in ephrin-A5-Fc treated mice. by Yona Goldshmit (205708)

    Published 2011
    “…<p>Immunohistochemical analysis of (A,B) GFAP, (C–F) EphA4 and (G,H) CSPG expression at 2 weeks after spinal cord hemisection and 2 weeks of ephrin-A5-Fc treatment indicated that there was robust GFAP staining in both treated and control mice (A,B). …”
  9. 129
  10. 130
  11. 131
  12. 132
  13. 133
  14. 134
  15. 135

    OCA alone markedly decreases and combined with Gemcitabine or Cisplatin abrogates growth of iCCA xenografts. by S. Di Matteo (6260417)

    Published 2019
    “…After 4 weeks, when the tumor size was approximately 100 mm<sup>3</sup> (T<sub>0</sub>) mice were treated with OCA (0.03% w/w, 30 mg/kg) alone or combined with Cisplatin (2.4 mg/Kg in 100 μl) or Gemcitabine (1.05 mg/Kg in 100 μl) for 5 additional weeks. a) Results are expressed as percent increase in tumor volume at different time points. …”
  16. 136

    Relationship between Differential Hepatic microRNA Expression and Decreased Hepatic Cytochrome P450 3A Activity in Cirrhosis by Raj Vuppalanchi (458660)

    Published 2013
    “…The relative expression (2<sup>-ΔΔCt</sup> mean ± SEM) of hepatic CYP3A4 mRNA was significantly higher in cirrhotic livers (21.76 ± 2.65 vs. 5.91 ± 1.29, P=2.04E-07) but their levels did not significantly correlate with hepatic CYP3A activity (r=-0.43, P=0.08).…”
  17. 137

    Supplementary Material for: SGLT2 inhibitors decrease overhydration and proteasuria in patients with chronic kidney disease: a longitudinal observational study by Schork A. (17795387)

    Published 2024
    “…Results: 42 patients (29 % with diabetic/hypertensive CKD, 31 % with IgA nephropathy; 88 % dapagliflozin 10 mg, 10 % dapagliflozin 5 mg, 2 % empagliflozin 20 mg; median eGFR 46 mL/min/1.73m² and albuminuria 1911 mg/g creatinine) participated in the study. …”
  18. 138

    Supplementary Material for: SGLT2 inhibitors decrease overhydration and proteasuria in patients with chronic kidney disease: a longitudinal observational study by Schork A. (17795387)

    Published 2024
    “…Results: 42 patients (29 % with diabetic/hypertensive CKD, 31 % with IgA nephropathy; 88 % dapagliflozin 10 mg, 10 % dapagliflozin 5 mg, 2 % empagliflozin 20 mg; median eGFR 46 mL/min/1.73m² and albuminuria 1911 mg/g creatinine) participated in the study. …”
  19. 139
  20. 140